Institut De Cancerologie De L Ouest — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

7 Recruiting

4 Completed trials

1 Countries active

23 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 6 Phase I/II: 1 Phase I: 1 Phase I (Other): 3

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Adenocarcinoma gastric 1 Non-small cell lung cancer metastatic 1 Metastatic malignant melanoma 1 Colorectal cancer 1 Small cell lung cancer metastatic 1 Breast cancer 1 Small cell lung cancer limited stage 1

Top IMPs

BEVACIZUMAB 2 FLUOROURACIL 2 OXALIPLATIN 2 BEMARITUZUMAB 1 CAPECITABINE 1 CETRORELIX 1 CETUXIMAB 1 CHORIOGONADOTROPIN ALFA 1 DENOSUMAB 1 DOCETAXEL 1 DURVALUMAB 1 FLUORODOPA (18F) 1

All trials

14 total

ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStat… Not authorised

2023-508473-86-00 Phase I (Other) 1 country
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle… Pending

2023-509729-33-00 Phase I 1 country
Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small… Pending

2024-514057-30-00 Phase I (Other) 1 country
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE) Recruiting

2024-516282-37-00 Phase II 1 country CETRORELIX; CHORIOGONADOTROPIN ALFA; FOLLITROPIN BETA; TAMOXIFEN CITRATE
ProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGa… Recruiting

2024-517658-90-00 Phase I (Other) 1 country GALLIUM (68GA), PENTIXAFOR
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu… Recruiting

2024-514560-10-00 Phase II 1 country BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN HYDROCHLORIDE TRI…
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Phase III 1 country BEVACIZUMAB; PREDNISOLONE; SODIUM CHLORIDE
Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting

2023-504618-31-00 Phase III 1 country
RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Recruiting

2022-502642-27-00 Phase I/II 1 country
Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or deno… Recruiting

2024-513248-27-00 Phase III 1 country DENOSUMAB; ZOLEDRONIC ACID MONOHYDRATE
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 Phase II 1 country DURVALUMAB
PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer Ended

2024-515850-26-00 Phase II 1 country FLUORODOPA (18F)
Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum) Ended

2024-512855-19-00 Phase II 1 country
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin… Ended

2024-514078-29-00 Phase II 1 country BEMARITUZUMAB; DOCETAXEL; FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN

Showing 1–14 of 14 trials

← All sponsors A–Z